Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,475,574
  • Shares Outstanding, K 85,353
  • Annual Sales, $ 371,210 K
  • Annual Income, $ -153,610 K
  • EBIT $ -332 M
  • EBITDA $ -313 M
  • 60-Month Beta 1.62
  • Price/Sales 9.36
  • Price/Cash Flow N/A
  • Price/Book 1.77

Options Overview Details

View History
  • Implied Volatility 55.85% ( -3.18%)
  • Historical Volatility 63.14%
  • IV Percentile 36%
  • IV Rank 27.61%
  • IV High 82.92% on 02/15/24
  • IV Low 45.53% on 08/26/24
  • Put/Call Vol Ratio 0.86
  • Today's Volume 7,835
  • Volume Avg (30-Day) 8,929
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 92,546
  • Open Int (30-Day) 84,752

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.20
  • Number of Estimates 11
  • High Estimate -0.74
  • Low Estimate -1.93
  • Prior Year 1.10
  • Growth Rate Est. (year over year) -209.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.41 +3.32%
on 12/20/24
55.50 -26.63%
on 12/02/24
-6.54 (-13.84%)
since 11/20/24
3-Month
39.41 +3.32%
on 12/20/24
59.07 -31.06%
on 11/11/24
-7.46 (-15.48%)
since 09/20/24
52-Week
39.41 +3.32%
on 12/20/24
91.10 -55.30%
on 02/22/24
-20.09 (-33.04%)
since 12/20/23

Most Recent Stories

More News
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?

What's going on with CRISPR Therapeutics (NASDAQ: CRSP) ? The company's shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the biotech hasn't...

CRSP : 40.72 (+0.83%)
1 big new Green Flag for CRISPR Therapeutics' Stock

CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver,...

CRSP : 40.72 (+0.83%)
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025....

CRSP : 40.72 (+0.83%)
IOVA : 7.38 (+2.22%)
VRTX : 397.27 (+0.16%)
3 Things You Need to Know if You Buy CRISPR Therapeutics Today

CRISPR Therapeutics (NASDAQ: CRSP) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA...

CRSP : 40.72 (+0.83%)
CRISPR Therapeutics Announces RMAT Designation for CTX112â„¢ Following Promising Phase 1 Data in CD19-Positive B-cell Malignancies

Preliminary data show CTX112â„¢ may benefit patients with certain B-cell malignancies; RMAT designation granted by FDA.Quiver AI SummaryCRISPR Therapeutics announced that preliminary data from its Phase...

CRSP : 40.72 (+0.83%)
2 Biotech Stocks to Buy Hand Over Fist in December

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500 . Will that trend continue in 2025?...

CRSP : 40.72 (+0.83%)
EXEL : 33.29 (-1.16%)
3 of the Best Growth Stocks You Can Buy for Less than $100

It's getting harder these days to find great growth stocks trading for less than $100 a share. It almost seems like a higher price is one of the criteria. But investors should know that there are plenty...

KBH : 65.86 (+0.08%)
CELH : 27.01 (-3.33%)
CRSP : 40.72 (+0.83%)
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%

Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and...

CRSP : 40.72 (+0.83%)
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?

On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies....

CRSP : 40.72 (+0.83%)
VRTX : 397.27 (+0.16%)
3 Monster Stocks in the Making

Godzilla and King Kong surely weren't born big. They began small and grew over time to their gargantuan sizes even if the movies don't tell their childhood stories.

VKTX : 42.25 (+1.83%)
CRSP : 40.72 (+0.83%)
SMMT : 17.87 (-2.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 42.97
2nd Resistance Point 41.99
1st Resistance Point 41.36
Last Price 40.72
1st Support Level 39.75
2nd Support Level 38.77
3rd Support Level 38.14

See More

52-Week High 91.10
Fibonacci 61.8% 71.35
Fibonacci 50% 65.25
Fibonacci 38.2% 59.16
Last Price 40.72
52-Week Low 39.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar